Clinical Trial Update: A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating IV/PO moxifloxacin for community-acquired pneumonia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Pneumonia

Drugs mentioned

• Moxifloxacin (moxifloxacin)

Snippet

Sponsor: Bayer | Conditions: Pneumonia | Phase 3 | Status: COMPLETED